Delisting of CompuGroup Medical will take effect at the end of 24.

Effective June 2025

 EQS News: CompuGroup Medical SE & Co. KGaA / Key word(s): Delisting
Effective June 2025

19.06.2025 / 11:21 CET/CEST
The issuer/publisher is responsible for the content of this announcement.

---------------------------------------------------------------------------

* Frankfurt Stock Exchange confirms delisting at the end of
Offer period of the public delisting offer of CVC Capital
Partners

* CGM shareholders can still purchase shares until 24 June 2025 at 24:00 CEST
offer

* Delisting Offer is not subject to any closing conditions and
Delisting is carried out regardless of the number of tendered
 Shares

* After delisting, significantly lower financial reporting and
limited tradability of shares to be expected

* Withdrawal from the stock exchange enables CompuGroup Medical to focus more on
the implementation of the long-term innovation and growth strategy

Koblenz - CompuGroup Medical SE & Co. KGaA ("CompuGroup Medical" or
"CGM") was informed today by the Frankfurt Stock Exchange that
that the requested revocation of the admission of its shares to trading on the
regulated market under ISIN DE000A288904 and in the sub-area of
regulated market with additional post-admission obligations (Prime Standard)
will take effect on 24 June 2025.

CompuGroup Medical is also listed on the stock exchanges in Berlin (in the sub-segment
Berlin Second Regulated Market), Düsseldorf, Hamburg, Hanover, Munich and
Stuttgart and the electronic trading system Tradegate Exchange
suggest that the shares of the company are immediately sold after the effective date of the
Delisting as of June 24, 2025, no longer in the over-the-counter market at these
exchanges and existing quotations with effect from this
Time can be set.

Once the delisting takes effect, all shares listed in
regulated market of the Frankfurt Stock Exchange
Transparency obligations, in particular the ad hoc publicity obligation and the
Obligation to prepare half-yearly financial reports and
Quarterly reports.

The planned delisting is part of a partnership between CGM and CVC Capital
Partners ("CVC"), which was announced on December 9, 2024. Together
CompuGroup Medical and CVC want to promote innovations in healthcare
which patients and
Healthcare providers worldwide benefit.

As part of this partnership, CVC published a voluntary
public takeover offer to all CGM shareholders. With the completion of the
Offer on 2 May 2025, the strategic partnership between CVC and
CGM officially came into force. Subsequently, CompuGroup Medical and CVC announced the
Signing of an agreement on the delisting of CGM.
For this purpose, CVC launched a public delisting offer on 23 May 2025 to
all shareholders of CompuGroup Medical in the amount of 22.00 euros in cash
Shareholders can accept the offer until 24 June 2025, 24:00
CEST. The Delisting Acquisition Offer is not subject to
Closing Conditions and will therefore be immediately effective upon expiry of the Acceptance Period
completed, regardless of the number of shares tendered.

After independent and careful review of the information published by CVC
Offer document has been signed by the Managing Directors, the
The Board of Directors and the Supervisory Board of CompuGroup Medical to the shareholders
recommended by CGM to accept the public delisting offer.

About CompuGroup Medical SE & Co. KGaA

CompuGroup Medical is one of the leading e-health companies worldwide and
generated annual sales of 1.15 billion euros in 2024. The
The company’s software products to support all medical and
organizational activities in doctor’s offices, pharmacies, laboratories,
Hospitals and social institutions that provide information services
for all those involved in healthcare and the web-based personal
Health records contribute to a safer and more efficient healthcare system.
The basis of CompuGroup Medical services is the unique
Customer base, including doctors, dentists, pharmacies, other healthcare professionals
in outpatient and inpatient facilities as well as insurance and
Pharmaceutical company. CompuGroup Medical maintains its own locations in 19
countries and sells products in 60 countries worldwide. More than 8,700
highly qualified employees stand for sustainable
Solutions for ever-growing demands in healthcare.

Important instructions

This press release does not constitute an offer to purchase or a
Invitation to submit an offer to sell shares in CompuGroup
Medical SE & Co. KGaA (the "CGM Shares"). The final terms
of the delisting acquisition offer and further the delisting acquisition offer
The relevant provisions are exclusively in the version published by the Federal Institute
for Financial Services Supervision authorized for publication
Offer Document. Caesar BidCo GmbH (the "Bidder") reserves the right
proposes to deviate from the final terms of the Delisting Offer
to deviate from the key points presented here, as far as this is legally permissible
Investors and holders of CGM shares are strongly advised to
Offer document and all other documents related to the Delisting Acquisition Offer
related documents as they contain important information
The offer document for the Delisting Acquisition Offer (in
German language and a non-binding English translation) with the
detailed conditions and other information on the delisting acquisition offer
is available along with further information on the Internet at
www.practice-public-offer.com published.

The Delisting Acquisition Offer will be made solely on the basis of the
applicable provisions of German law, in particular the
Securities Acquisition and Takeover Act (WpÜG), Stock Exchange Act (BörsG)
and certain securities laws of the United States
from America ("United States") via cross-border
Delisting acquisition offers are carried out. The delisting acquisition offer is
not in accordance with the legal requirements of other
legal systems other than the Federal Republic of Germany or the United
States (where applicable). Accordingly, outside
the Federal Republic of Germany or the United States (as far as
applicable) no notices, notifications, approvals or
Approvals for the Delisting Acquisition Offer have been submitted, initiated or
Investors and holders of CGM shares cannot rely on
invoked by the investor protection laws of a jurisdiction other than the
Federal Republic of Germany or the United States (as applicable)
Subject to the terms and conditions described in the Offer Document
Exceptions and, where appropriate, by the relevant supervisory authorities
exemptions granted, no delisting acquisition offer will be made, either directly
nor indirectly, in those jurisdictions where this
would constitute a violation of the respective national law. This
This press release may not be reproduced, in whole or in part, in any jurisdiction
published or otherwise distributed in which the
Delisting acquisition offer in accordance with applicable national law
would be prohibited.

The Bidder and/or persons acting jointly with the Bidder within the meaning of
of Section 2 Para. 5 WpÜG and/or their subsidiaries within the meaning of Section 2 Para.
6 WpÜG, CGM shares may be acquired during the term of the delisting offer
in a manner other than pursuant to the Delisting Acquisition Offer on the stock exchange or
acquire over-the-counter or conclude corresponding acquisition agreements,
provided that this occurs outside the United States and in accordance with the
applicable German law, in particular the WpÜG, and
provided that the Delisting Offer Price is increased in such a way
that this may be outside the delisting acquisition offer
higher consideration paid. Information about corresponding
Acquisitions or acquisition agreements are made in accordance with Section 23 (2) WpÜG in
Federal Gazette. This information is also published in a
non-binding English translation on the Bidder's website
published at www.practice-public-offer.de.

The delisting acquisition offer announced with this press release
refers to shares of a German company listed for trading on the
Frankfurt Stock Exchange and is subject to the
Publication obligations and regulations and the
Publication practice in the Federal Republic of Germany for
listed companies and are located in certain material
Aspects of those in the United States and other jurisdictions
This press release was prepared in accordance with German style and practice
to comply with the laws of the Federal Republic of Germany.
contained elsewhere, including in the Offer Document, relating to the
Bidder and the financial figures relating to CGM are in accordance
with the regulations applicable in the Federal Republic of Germany and not
in accordance with the United States generally accepted
accounting principles; they may therefore not be consistent with
Financial indicators comparable to those relating to US companies
or companies from legal systems other than the Federal Republic of
Germany.

The Delisting Offer will be made in the United States on the
Basis of the so-called cross-border Tier 2 exemption from
certain provisions of the US Securities Exchange Act of 1934 as amended
as amended (the "Exchange Act"). This exception
enables the bidder to exercise certain substantive and procedural
Exchange Act provisions for delisting tender offers by
that he respects the law or practice of his home jurisdiction
and exempts the bidder from compliance with certain other
provisions of the Exchange Act. Shareholders from the United States will
pointed out that the CGM is not involved in a US
Stock Exchange, does not meet the regular requirements of the
Securities Act and does not file any reports with the
US Securities and Exchange Commission.

CGM shareholders with their residence, registered office or habitual abode in the
United States, should note that the
Delisting offer relates to securities of a company that is a
foreign private issuer within the meaning of
Exchange Act and whose shares are not subject to Section 12 of the Exchange Act
The Delisting Offer is being made in the United States
States on the basis of the so-called cross-border Tier 2 exemption
from certain requirements of the Exchange Act and is generally subject
the disclosure and other rules and procedures in the
Federal Republic of Germany, which deviates from the regulations and procedures in
the United States. To the extent that the Delisting Acquisition Offer
subject to U.S. securities laws, these laws apply exclusively
to CGM shareholders with their residence, registered office or habitual abode in the
United States, and no other person shall have any claim
from these laws.

Any contract entered into with the Company as a result of the acceptance of the Delisting Acquisition Offer
Bidder is subject exclusively to the laws of the
Federal Republic of Germany and is to be interpreted accordingly. For shareholders
from the United States (or from jurisdictions other than
Germany) it can be difficult to assert rights and claims arising in the
in connection with the Delisting Acquisition Offer, in accordance with the provisions
the US Securities Act (or other laws known to them)
enforce, as the Bidder and CGM are located outside the United
States (or the jurisdiction in which the shareholder is resident)
and their respective managers and board members are
Residence outside the United States (or the jurisdiction in which
the shareholder is resident). It may be impossible to
Non-US companies or their officers and directors
a non-US court for violations of US securities laws
It may also be impossible to sue a non-US company
or its subsidiaries to submit to the judgment of a
to be submitted to a US court.

To the extent that this press release contains forward-looking statements,
These are not statements of fact and are replaced by the words
"intend", "will" and similar expressions. These
Statements reflect the intentions, assumptions or current expectations and
assumptions of the Bidder and the persons acting jointly with it.
Such forward-looking statements are based on current, best
knowledge of the Bidder’s plans, estimates and forecasts and
of persons acting jointly with it, but do not constitute a guarantee for
their future accuracy (this applies in particular to circumstances that
outside the sphere of influence of the Bidder or the jointly
acting persons). Forward-looking statements are subject to risks
and uncertainties, most of which are difficult to predict and in
generally beyond the control of the bidder or the joint ventures
It should be taken into account that the
actual results or consequences in the future could differ materially from those
the forward-looking statements stated or contained
It cannot be ruled out that the Bidder and the
persons acting jointly with it, their rights contained in documents or communications or
change the intentions and assessments expressed in the offer document
become.


---------------------------------------------------------------------------

19.06.2025 CET/CEST Publication of a corporate news/financial news,
transmitted by EQS News - a service of the EQS Group.
The issuer/publisher is responsible for the content of this announcement.

The EQS Distribution Services include statutory reporting obligations, corporate
News/financial news and press releases.
Media archive at https://eqs-news.com

---------------------------------------------------------------------------

Language: German
Company: CompuGroup Medical SE & Co. KGaA
Maria Trost 21
56070 Koblenz
 Germany
Phone: +49 (0)160 3630362
Fax: +49 (0)261 8000 3200
Email: [email protected]
Internet: www.cgm.com
ISIN: DE000A288904
WKN: A28890
Indices: SDAX, TecDAX
Stock exchanges: Regulated market in Frankfurt (Prime Standard);
Over-the-counter trading in Berlin, Düsseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2157758



End of message EQS News Service
---------------------------------------------------------------------------

2157758 19.06.2025 CET/CEST